|
1
|
Arnold M, Morgan E, Rumgay H, Mafra A,
Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S
and Soerjomataram I: Current and future burden of breast cancer:
Global statistics for 2020 and 2040. Breast. 66:15–23. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giaquinto AN, Sung H, Miller KD, Kramer
JL, Newman LA, Minihan A, Jemal A and Siegel RL: Breast cancer
statistics, 2022. CA Cancer J Clin. 72:524–541. 2022.PubMed/NCBI
|
|
3
|
Tornai M, Hugg J, Patt B, et al: Abstract
PO5-18-01: Cancer detection rate meta-analysis comparison of
contemporary dense-breast supplemental screening modalities. Cancer
Res. 2024, https://aacrjournals.org/cancerres/article/84/9_Supplement/PO5-18-01/744391/Abstract-PO5-18-01-Cancer-Detection-Rate-Meta.
View Article : Google Scholar
|
|
4
|
Li J, He D, Bi Y and Liu S: The emerging
roles of exosomal miRNAs in breast cancer progression and potential
clinical applications. Breast Cancer (Dove Med Press). 15:825–840.
2023.PubMed/NCBI
|
|
5
|
Thakur P, Dahiya H, Kaushal A, Gupta VK,
Saini AK and Saini RV: Exosomal miRNAs as Next-generation therapy
vehicles in breast cancer. Curr Gene Ther. 23:330–342. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Di Bella MA: Overview and update on
extracellular vesicles: Considerations on exosomes and their
application in modern medicine. Biology. 11:8042022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Simeone P, Bologna G, Lanuti P,
Pierdomenico L, Guagnano MT, Pieragostino D, Del Boccio P, Vergara
D, Marchisio M, Miscia S and Mariani-Costantini R: Extracellular
vesicles as signaling mediators and disease biomarkers across
biological barriers. Int J Mol Sci. 21:25142020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Di Martino MT, Arbitrio M, Caracciolo D,
Cordua A, Cuomo O, Grillone K, Riillo C, Caridà G, Scionti F,
Labanca C, et al: miR-221/222 as biomarkers and targets for
therapeutic intervention on cancer and other diseases: A systematic
review. Mol Ther Nucleic Acids. 27:1191–1224. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim J, Siverly AN, Chen D, Wang M, Yuan Y,
Wang Y, Lee H, Zhang J, Muller WJ, Liang H, et al: Ablation of
miR-10b suppresses oncogene-induced mammary tumorigenesis and
metastasis and reactivates tumor-suppressive pathways. Cancer Res.
76:6424–6435. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ashekyan O, Abdallah S, Shoukari AA,
Chamandi G, Choubassy H, Itani ARS, Alwan N and Nasr R: Spotlight
on exosomal Non-coding RNAs in breast cancer: An in silico analysis
to identify potential lncRNA/circRNA-miRNA-target axis. Int J Mole
Sci. 23:83512022. View Article : Google Scholar
|
|
12
|
Lee A, Moon BI and Kim TH: BRCA1/BRCA2
pathogenic variant breast cancer: Treatment and prevention
strategies. Ann Lab Med. 40:114–121. 2020. View Article : Google Scholar :
|
|
13
|
Admoun C and Mayrovitz HN: The etiology of
breast cancer. Breast Cancer. Mayrovitz HN: Exon Publications;
Brisbane: 2022, View Article : Google Scholar
|
|
14
|
Obeagu EI and Obeagu GU: Breast cancer: A
review of risk factors and diagnosis. Medicine (Baltimore).
103:e369052024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bazyka DA, Lytvynenko OO and Litvinenko
OO: Influence of ionizing radiation on the development of breast
cancer. Probl Radiac Med Radiobiol. 28:22–48. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Petrović D, Šćepanović B, Spirovski M,
Nikin Z and Prvulović Bunović N: Comparative diagnostic efficacy of
four breast imaging modalities in dense breasts: A Single-center
retrospective study. Biomedicines. 13:17502025. View Article : Google Scholar
|
|
17
|
Wanders JO, Holland K, Veldhuis WB, Mann
RM, Pijnappel RM, Peeters PH, van Gils CH and Karssemeijer N:
Volumetric breast density affects performance of digital screening
mammography. Breast Cancer Res Treat. 162:95–103. 2017. View Article : Google Scholar :
|
|
18
|
Brill JV: Screening for cancer: The
economic, medical, and psychosocial issues. Am J Manag Care.
26(Suppl): S300–S306. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kalluri R and LeBleu VS: The biology,
function, and biomedical applications of exosomes. Science.
367:eaau69772020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zemanek T, Danisovic L and Nicodemou A:
Exosomes, their sources, and possible uses in cancer therapy in the
era of personalized medicine. J Cancer Res Clin Oncol. 151:162024.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tabatabai TS, Alizadeh M, Rezakhani L,
Tabatabai TS, Ehterami A, Kloucheh SG, Kebria MM, Vaez A and Salehi
M: Unlocking the potential of EXOs in regenerative medicine: A
comprehensive review. Tissue Cell. 97:1030682025. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Larios J, Mercier V, Roux A and Gruenberg
J: ALIX- and ESCRT-III-dependent sorting of tetraspanins to
exosomes. J Cell Biol. 219:e2019041132020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arya SB, Collie SP and Parent CA: The
ins-and-outs of exosome biogenesis, secretion, and internalization.
Trends Cell Biol. 34:90–108. 2024. View Article : Google Scholar
|
|
24
|
Fayyazpour P, Fayyazpour A, Abbasi K,
Vaez-Gharamaleki Y, Zangbar MS, Raeisi M and Mehdizadeh A: The role
of exosomes in cancer biology by shedding light on their lipid
contents. Pathol Res Pract. 250:1548132023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abdullah M, Nakamura T, Ferdous T, Gao Y,
Chen Y, Zou K and Michikawa M: Cholesterol regulates exosome
release in cultured astrocytes. Front Immunol. 12:7225812021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee YJ, Shin KJ and Chae YC: Regulation of
cargo selection in exosome biogenesis and its biomedical
applications in cancer. Exp Mol Med. 56:877–889. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Toribio V and Yáñez-Mó M: Tetraspanins
interweave EV secretion, endosomal network dynamics and cellular
metabolism. Eur J Cell Biol. 101:1512292022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gurung S, Perocheau D, Touramanidou L and
Baruteau J: The exosome journey: From biogenesis to uptake and
intracellular signalling. Cell Commun Signal. 19:472021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ariotti N, Wu Y, Okano S, Gambin Y,
Follett J, Rae J, Ferguson C, Teasdale RD, Alexandrov K and Meunier
FA: An inverted CAV1 (caveolin 1) topology defines novel
autophagy-dependent exosome secretion from prostate cancer cells.
Autophagy. 17:2200–2216. 2021. View Article : Google Scholar :
|
|
30
|
Chu YD, Chen MC, Yeh CT and Lai MW:
Hijacking host extracellular vesicle machinery by hepatotropic
viruses: Current understandings and future prospects. J Biomed Sci.
31:972024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sarkar N and Kumar A: Paradigm shift:
MicroRNAs interact with target gene promoters to cause
transcriptional gene activation or silencing. Exp Cell Res.
444:1143722025. View Article : Google Scholar
|
|
32
|
Li C, Zhou T, Chen J, Li R, Chen H, Luo S,
Chen D, Cai C and Li W: The role of Exosomal miRNAs in cancer. J
Trans Med. 20:62022. View Article : Google Scholar
|
|
33
|
Zhang Y, Liu Y, Liu H and Tang WH:
Exosomes: Biogenesis, biologic function and clinical potential.
Cell Biosci. 9:192019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tran N: Cancer Exosomes as miRNA
Factories. Trends Cancer. 2:329–331. 2016. View Article : Google Scholar
|
|
35
|
Tang J, He J, Feng C and Tu C: Exosomal
MiRNAs in osteosarcoma: Biogenesis and biological functions. Front
Pharmacol. 13:9020492022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun Z, Shi K, Yang S, Liu J, Zhou Q, Wang
G, Song J, Li Z, Zhang Z and Yuan W: Effect of exosomal miRNA on
cancer biology and clinical applications. Mol Cancer. 17:1472018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hóbor F, Dallmann A, Ball N, Cicchini C,
Battistelli C, Ogrodowicz RW, Christodoulou E, Martin SR, Castello
A, Tripodi M, et al: A cryptic RNA-binding domain mediates Syncrip
recognition and exosomal partitioning of miRNA targets. Nat Commun.
9:8312018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Santangelo L, Giurato G, Cicchini C,
Montaldo C, Mancone C, Tarallo R, Battistelli C, Alonzi T, Weisz A
and Tripodi M: The RNA-binding protein SYNCRIP is a component of
the hepatocyte exosomal machinery controlling MicroRNA sorting.
Cell Rep. 173:799–808. 2016. View Article : Google Scholar
|
|
39
|
Jones K, Phan A, Zhang C, Haar L and Lynch
T: Abstract MP219: Hnrnpa2b1-dependent selective sorting of
Mir-486a-5p Into Msc-derived exosomes contributes to
cardioprotection. Circulation Res. 129:2021. View Article : Google Scholar
|
|
40
|
Zhou X, Wang L, Zou W, Chen X, Roizman B
and Zhou G: hnRNPA2B1 associated with recruitment of RNA into
exosomes plays a key role in herpes simplex virus 1 release from
infected cells. J Virology. 94:e00367–20. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ma L, Singh J and Schekman R: Two
RNA-binding proteins mediate the sorting of miR223 from
mitochondria into exosomes. Elife. 12:e858782023. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Colombo M, Raposo G and Théry C:
Biogenesis, secretion, and intercellular interactions of exosomes
and other extracellular vesicles. Annu Rev Cell Dev Biol.
30:255–289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hessvik NP and Llorente A: Current
knowledge on exosome biogenesis and release. Cell Mol Life Sci.
75:193–208. 2018. View Article : Google Scholar
|
|
44
|
Wani S and Kaul D: Cancer cells govern
miR-2909 exosomal recruitment through its 3'- end
post-transcriptional modification. Cell Biochem Funct. 36:106–111.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Horbay R, Hamraghani A, Ermini L, Holcik
S, Beug ST and Yeganeh B: Role of ceramides and lysosomes in
extracellular vesicle biogenesis, cargo sorting and release. Int J
Mol Sci. 23:153172022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hoshino A, Kim HS, Bojmar L, Gyan KE,
Cioffi M, Hernandez J, Zambirinis CP, Rodrigues G, Molina H,
Heissel S, et al: Extracellular vesicle and particle biomarkers
define multiple human cancers. Cell. 182:1044–1061.e1018. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
O'Bryan S, Dong S, Mathis M and Alahari S:
The roles of oncogenic miRNAs and their therapeutic importance in
breast cancer. Eur J Cancer. 72:1–11. 2017. View Article : Google Scholar
|
|
48
|
Syed RU, Banu H, Alshammrani A, Alshammari
MD, G SK, Kadimpati KK, Khalifa AAS, Aboshouk NAM, Almarir AM,
Hussain A and Alahmed FK: MicroRNA-21 (miR-21) in breast cancer:
From apoptosis dysregulation to therapeutic opportunities. Pathol
Res Pract. 262:1555722024. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Giordo R, Ahmadi FAM, Husaini NA,
Al-Nuaimi NRAM, Ahmad SMS, Pintus G and Zayed H: microRNA 21 and
long non-coding RNAs interplays underlie cancer pathophysiology: A
narrative review. Noncoding RNA Res. 9:831–852. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang W, Chen CJ and Guo GL: MiR-155
promotes the proliferation and migration of breast cancer cells via
targeting SOCS1 and MMP16. Eur Rev Med Pharmacol Sci. 22:7323–7332.
2018.PubMed/NCBI
|
|
51
|
Grimaldi AM, Nuzzo S, Condorelli G,
Salvatore M and Incoronato M: Prognostic and clinicopathological
significance of MiR-155 in breast cancer: A systematic review. Int
J Mol Sci. 21:58342020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu Y, Zhao Q, Xi T, Zheng L and Li X:
MicroRNA-9 as a paradoxical but critical regulator of cancer
metastasis: Implications in personalized medicine. Genes Dis.
8:759–768. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li X, Zeng Z, Wang J, Wu Y, Chen W, Zheng
L, Xi T, Wang A and Lu Y: MicroRNA-9 and breast cancer. Biomed
Pharmacother. 122:1096872020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ueda S, Takanashi M, Sudo K, Kanekura K
and Kuroda M: miR-27a ameliorates chemoresistance of breast cancer
cells by disruption of reactive oxygen species homeostasis and
impairment of autophagy. Lab Invest. 100:863–873. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang H, Lang TY, Zou DL, Zhou L, Lou M,
Liu JS, Li YZ, Ding DY, Li YC, Zhang N, et al: miR-520b promotes
breast cancer stemness through Hippo/YAP signaling pathway. Onco
Targets Ther. 12:11691–11700. 2019. View Article : Google Scholar
|
|
56
|
Soheilifar MH, Vaseghi H, Seif F, Ariana
M, Ghorbanifar S, Habibi N, Papari Barjasteh F and Pornour M:
Concomitant overexpression of mir-182-5p and mir-182-3p raises the
possibility of IL-17-producing Treg formation in breast cancer by
targeting CD3d, ITK, FOXO1, and NFATs: A meta-analysis and
experimental study. Cancer Sci. 112:589–603. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Murugesan M and Premkumar K: Integrative
miRNA-mRNA functional analysis identifies miR-182 as a potential
prognostic biomarker in breast cancer. Mol Omics. 17:533–543. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fei, Zhang J, Zhong L, Wang L, Liu Y, Wang
Y, Peng L and Guo B: Upregulated microRNA-301a in breast cancer
promotes tumor metastasis by targeting PTEN and activating
Wnt/β-catenin signaling. Gene. 535:191–197. 2014. View Article : Google Scholar
|
|
59
|
Santana T, de Oliveira Passamai L, de
Miranda FS, Borin TF, Borges GF, Luiz WB and Campos LCG: The role
of miRNAs in the prognosis of Triple-Negative breast cancer: A
systematic review and meta-analysis. Diagnostics (Basel).
13:1272022. View Article : Google Scholar
|
|
60
|
Wang Y, Zeng G and Jiang Y: The emerging
roles of miR-125b in cancers. Cancer Manag Res. 12:1079–1088. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chu C, Liu X, Bai X, Zhao T, Wang M, Xu R,
Li M, Hu Y, Li W, Yang L, et al: MiR-519d suppresses breast cancer
tumorigenesis and metastasis via targeting MMP3. Int J Biol Sci.
14:228–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Deng X, Zhao Y and Wang B:
miR-519d-mediated downregulation of STAT3 suppresses breast cancer
progression. Oncol Rep. 34:2188–2194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ma H, Liu T, Xu Y, Wang X, Wang J and Liu
X: MiR-519d and miR-328-3p combinatorially suppress breast cancer
progression. Onco Targets Ther. 13:12987–12997. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Li J, Li Y and Cheng H: Circ-RPPH1
knockdown retards breast cancer progression via miR-328-3p-mediated
suppression of HMGA2. Clin Breast Cancer. 22:e286–e295. 2022.
View Article : Google Scholar
|
|
65
|
Yin M, Zhang Z and Wang Y: Anti-tumor
effects of miR-34a by regulating immune cells in the tumor
microenvironment. Cancer Med. 12:11602–11610. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Li L, Yuan L, Luo J, Gao J, Guo J and Xie
X: MiR-34a inhibits proliferation and migration of breast cancer
through down-regulation of Bcl-2 and SIRT1. Clin Exp Med.
13:109–117. 2013. View Article : Google Scholar
|
|
67
|
Li ZH, Weng X, Xiong QY, Tu JH, Xiao A,
Qiu W, Gong Y, Hu EW, Huang S and Cao YL: miR-34a expression in
human breast cancer is associated with drug resistance. Oncotarget.
8:106270–106282. 2017. View Article : Google Scholar :
|
|
68
|
Fontana A, Barbano R, Dama E, Pasculli B,
Rendina M, Morritti MG, Melocchi V, Castelvetere M, Valori VM,
Ravaioli S, et al: Combined analysis of miR-200 family and its
significance for breast cancer. Sci Rep. 11:29802021. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Song C, Liu LZ, Pei XQ, Liu X, Yang L, Ye
F and Xie X, Chen J, Tang H and Xie X: miR-200c inhibits breast
cancer proliferation by targeting KRAS. Oncotarget. 6:34968–34978.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Hong T, Ding J and Li W: miR-7 reverses
breast cancer resistance to chemotherapy by targeting MRP1 and
BCL2. Onco Targets Ther. 12:11097–11105. 2019. View Article : Google Scholar
|
|
71
|
Kalinowski FC, Brown RAM, Ganda C, Giles
KM, Epis MR, Horsham J and Leedman PJ: microRNA-7: A tumor
suppressor miRNA with therapeutic potential. Int J Biochem Cell
Biol. 54:312–317. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang Z, Hu S, Li X, Liu Z, Han D, Wang Y,
Wei L, Zhang G and Wang X: MiR-16-5p suppresses breast cancer
proliferation by targeting ANLN. BMC Cancer. 21:11882021.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ni Q, Qian Y, Yi T, Zhou J, Sang K and Pan
C: miR-16-5p may modulate migration and proliferation through TP53
and LncRNA-NEAT1 in triple-negative breast cancer. Gene Rep.
37:1020382024. View Article : Google Scholar
|
|
74
|
Piergentili R, Marinelli E, Cucinella G,
Lopez A, Napoletano G, Gullo G and Zaami S: miR-125 in breast
cancer etiopathogenesis: An emerging role as a biomarker in
differential diagnosis, regenerative medicine, and the challenges
of personalized medicine. Noncoding RNA. 10:162024.PubMed/NCBI
|
|
75
|
Luo Y, Wang X, Niu W, Wang H, Wen Q, Fan
S, Zhao R, Li Z, Xiong W, Peng S, et al: Elevated microRNA-125b
levels predict a worse prognosis in HER2-positive breast cancer
patients. Oncol Lett. 13:867–874. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Pan S, Zhao X, Shao C, Fu B, Huang Y,
Zhang N, Dou X, Zhang Z, Qiu Y, Wang R, et al: STIM1 promotes
angiogenesis by reducing exosomal miR-145 in breast cancer
MDA-MB-231 cells. Cell Death Dis. 12:382021. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Contreras-Sanzón E, Carlos-Reyes Á,
Sierra-Martínez M, Acosta-Altamirano G, Luna-Rivero C, Núñez-Corona
D, García-Hernández AP, Ibarra-Sierra E, Vidrio-Morgado H,
Alvarez-Sánchez ME, et al: Metastatic breast tumors downregulate
miR-145 regulating the hypoxia-induced vasculogenic mimicry. Transl
Oncol. 33:1016802023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Baxter DE, Allinson LM, Al Amri WS,
Poulter JA, Pramanik A, Thorne JL, Verghese ET and Hughes TA:
MiR-195 and its target SEMA6D regulate chemoresponse in breast
cancer. Cancers (Basel). 13:59792021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wang Y, Zhang X, Zou C, Kung HF, Lin MC,
Dress A, Wardle F, Jiang BH and Lai L: miR-195 inhibits tumor
growth and angiogenesis through modulating IRS1 in breast cancer.
Biomed Pharmacother. 80:95–101. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chaudhari R, Nasra S, Meghani N and Kumar
A: MiR-206 conjugated gold nanoparticle based targeted therapy in
breast cancer cells. Sci Rep. 12:47132022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Babaeenezhad E, Abdolvahabi Z, Asgharzadeh
S, Abdollahi M, Shakeri S, Moradi Sarabi M and Yarahmadi S:
Potential function of microRNA miRNA-206 in breast cancer
pathogenesis: Mechanistic aspects and clinical implications. Pathol
Res Pract. 260:1554542024. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sun D, Li C and Zhang F: MicroRNA-206
suppresses growth and metastasis of breast cancer stem cells via
blocking EVI-1-mediated CALR expression. PLoS One. 17:e02749192022.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Tian Y, Chen ZH, Wu P, Zhang D, Ma Y, Liu
XF, Wang X, Ding D, Cao XC and Yu Y: MIR497HG-derived miR-195 and
miR-497 mediate tamoxifen resistance via PI3K/AKT signaling in
breast cancer. Adv Sci (Weinh). 10:e22048192023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Tao S, Li H, Ma X, Lian B, He J, Gao Y and
Li J: Methylation-mediated silencing of MicroRNA-497 promotes
breast cancer progression through up-regulation of Mucin1. Front
Oncol. 10:5520992020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Plantamura I, Cataldo A, Cosentino G and
Iorio MV: miR-205 in breast cancer: State of the art. Int J Mol
Sci. 22:272021. View Article : Google Scholar :
|
|
86
|
Shen Y, Xu Y, Huang L, Chi Y and Meng L:
MiR-205 suppressed the malignant behaviors of breast cancer cells
by targeting CLDN11 via modulation of the epithelial-to-mesenchymal
transition. Aging (Albany NY). 13:13073–13086. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ouyang B, Bi M, Jadhao M, Bick G and Zhang
X: miR-205 regulates tamoxifen resistance by targeting estrogen
receptor coactivator MED1 in human breast cancer. Cancers.
16:39922024. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Hong BS, Ryu HS, Kim N, Kim J, Lee E, Moon
H, Kim KH, Jin MS, Kwon NH, Kim S, et al: Tumor suppressor
miRNA-204-5p regulates growth, metastasis, and immune
microenvironment remodeling in breast cancer. Cancer Res.
79:1520–1534. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Yang F, Bian Z, Xu P, Sun S and Huang Z:
MicroRNA-204-5p: A pivotal tumor suppressor. Cancer Med.
12:3185–3200. 2023. View Article : Google Scholar :
|
|
90
|
Bermúdez M, Martínez-Barajas MG,
Bueno-Urquiza LJ, López-Gutiérrez JA, Villegas-Mercado CE and
López-Camarillo C: Role of MicroRNA-204 in regulating the hallmarks
of breast cancer: An update. Cancers. 16:28142024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Soung YH, Chung H, Yan C, Fesler A, Kim H,
Oh ES, Ju J and Chung J: Therapeutic potential of chemically
modified miR-489 in triple-negative breast cancers. Cancers.
12:22092020. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Soni M, Patel Y, Markoutsa E, Jie C, Liu
S, Xu P and Chen H: Autophagy, cell viability, and chemoresistance
are regulated by miR-489 in breast cancer. Mol Cancer Res.
16:1348–1360. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Menon A, Abd-Aziz N, Khalid K, Poh C and
Naidu R: miRNA: A promising therapeutic target in cancer. Int J Mol
Sci. 23:115022022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Nahmias Y, Grobman GY and Vidavsky N:
Inhibiting pathological calcium phosphate mineralization:
Implications for disease progression. ACS Appl Mater Interfaces.
16:18344–18359. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Shin K, Laohajaratsang M, Men S, Figueroa
B, Dintzis S and Fu D: Quantitative chemical imaging of breast
calcifications in association with neoplastic processes.
Theranostics. 10:5865–5878. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Li XJ, Ren ZJ, Tang JH and Yu Q: Exosomal
MicroRNA MiR-1246 promotes cell proliferation, invasion and drug
resistance by targeting CCNG2 in breast cancer. Cell Physiol
Biochem. 44:1741–1748. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Hannafon BN, Trigoso YD, Calloway CL, Zhao
YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC and Ding WQ:
Plasma exosome microRNAs are indicative of breast cancer. Breast
Cancer Res. 18:902016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Eichelser C, Stückrath I, Müller V,
Milde-Langosch K, Wikman H, Pantel K and Schwarzenbach H: Increased
serum levels of circulating exosomal microRNA-373 in
receptor-negative breast cancer patients. Oncotarget. 5:9650–9663.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sueta A, Yamamoto Y and Iwase H: The role
of exosomal microRNAs; focus on clinical applications in breast
cancer. Cancer Drug Resist. 2:847–861. 2019.PubMed/NCBI
|
|
100
|
Tang LB, Ma SX, Chen ZH, Huang QY, Wu LY,
Wang Y, Zhao RC and Xiong LX: Exosomal microRNAs: Pleiotropic
impacts on breast cancer metastasis and their clinical
perspectives. Biology (Basel). 10:3072021.PubMed/NCBI
|
|
101
|
Kan JY, Shih SL, Yang SF, Chu PY, Chen FM,
Li CL, Wu YC, Yeh YT, Hou MF and Chiang CP: Exosomal microRNA-92b
is a diagnostic biomarker in breast cancer and targets
survival-related MTSS1L to promote tumorigenesis. Int J Mol Sci.
25:12952024. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Xie QH, Zheng JQ, Ding JY, Wu YF, Liu L,
Yu ZL and Chen G: Exosome-mediated immunosuppression in tumor
microenvironments. Cells. 11:19462022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Singh T, Kaushik M, Mishra LC, Behl C,
Singh V and Tuli HS: Exosomal miRNAs as novel avenues for breast
cancer treatment. Front Genet. 14:11347792023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Xu J, Zhao X, Liang X, Guo D, Wang J, Wang
Q and Tang X: Development of miRNA-based PROTACs targeting Lin28
for breast cancer therapy. Sci Adv. 10:eadp03342024. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gomez IG, MacKenna DA, Johnson BG, Kaimal
V, Roach AM, Ren S, Nakagawa N, Xin C, Newitt R, Pandya S, et al:
Anti-microRNA-21 oligonucleotides prevent Alport nephropathy
progression by stimulating metabolic pathways. J Clin Invest.
125:141–156. 2015. View Article : Google Scholar :
|
|
106
|
Dogra P, Shinglot V, Ruiz-Ramírez J, Cave
J, Butner JD, Schiavone C, Duda DG, Kaseb AO, Chung C, Koay EJ, et
al: Translational modeling-based evidence for enhanced efficacy of
standard-of-care drugs in combination with anti-microRNA-155 in
non-small-cell lung cancer. MedRxiv. Mar 15–2024. View Article : Google Scholar
|
|
107
|
Hong DS, Kang YK, Borad M, Sachdev J,
Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, et al: Phase 1
study of MRX34, a liposomal miR-34a mimic, in patients with
advanced solid tumours. Br J Cancer. 122:1630–1637. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Abate M, Lombardi A, Luce A, Porru M,
Leonetti C, Bocchetti M, Campani V, De Rosa G, Graziano SF, Nele V,
et al: Fluorescent nanodiamonds as innovative delivery systems for
MiR-34a replacement in breast cancer. Mol Ther Nucleic Acids.
33:127–141. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Yan G, Xiao Q, Zhao J, Chen H, Xu Y, Tan M
and Peng L: Brucea javanica derived exosome-like nanovesicles
deliver miRNAs for cancer therapy. J Control Release. 367:425–440.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Wang J, Wang Q, Guan Y, Sun Y, Wang X,
Lively K, Wang Y, Luo M, Kim JA, Murphy EA, et al: Breast cancer
cell-derived microRNA-155 suppresses tumor progression via
enhancing immune cell recruitment and antitumor function. J Clin
Invest. 132:e1572482022. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang S, Zhang J, Wang Y and Chen M:
Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery
of doxorubicin and miR-542-3p for triple negative breast cancer
therapy. Nanomedicine. 12:411–420. 2016. View Article : Google Scholar
|
|
112
|
Kousar K, Ahmad T, Abduh MS, Kanwal B,
Shah SS, Naseer F and Anjum S: miRNAs in regulation of tumor
microenvironment, chemotherapy resistance, immunotherapy modulation
and miRNA therapeutics in cancer. Int J Mol Sci. 23:138222022.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhou H, Jia W, Lu L and Han R: MicroRNAs
with multiple targets of immune checkpoints, as a potential
sensitizer for immune checkpoint inhibitors in breast cancer
treatment. Cancers. 15:8242023. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Ohno S, Takanashi M, Sudo K, Ueda S,
Ishikawa A, Matsuyama N, Fujita K, Mizutani T, Ohgi T, Ochiya T, et
al: Systemically injected exosomes targeted to EGFR deliver
antitumor microRNA to breast cancer cells. Mol Ther. 21:185–191.
2013. View Article : Google Scholar
|
|
115
|
Deng S, Wang M, Wang C, Zeng Y, Qin X, Tan
Y, Liang B and Cao Y: p53 downregulates PD-L1 expression via
miR-34a to inhibit the growth of triple-negative breast cancer
cells: A potential clinical immunotherapeutic target. Mol Biol Rep.
50:577–587. 2023. View Article : Google Scholar
|
|
116
|
Huang X and Xie X, Wang H, Xiao X, Yang L,
Tian Z, Guo X, Zhang L, Tang H and Xie X: PDL1 And LDHA act as
ceRNAs in triple negative breast cancer by regulating miR-34a. J
Exp Clin Cancer Res. 36:1292017. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Khanicheragh P, Abbasi-Malati Z, Saghebasl
S, Hassanpour P, Milani SZ, Rahbarghazi R and Hasani A: Exosomes
and breast cancer angiogenesis; Highlights in intercellular
communication. Cancer Cell Int. 24:4022024. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Linares-Rodríguez M, Blancas I and
Rodríguez-Serrano F: The predictive value of blood-derived exosomal
miRNAs as biomarkers in breast cancer: A systematic review. Clin
Breast Cancer. 25:e48–e55.e15. 2025. View Article : Google Scholar
|
|
119
|
Li H and Tie XJ: Exploring research
progress in studying serum exosomal miRNA-21 as a molecular
diagnostic marker for breast cancer. Clin Transl Oncol.
26:2166–2171. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Piasecka D, Braun M, Kordek R, Sądej R and
Romanska H: MicroRNAs in regulation of triple-negative breast
cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zhang Z, Zhang L, Yu G, Sun Z, Wang T,
Tian X, Duan X and Zhang C: Exosomal miR-1246 and miR-155 as
predictive and prognostic biomarkers for trastuzumab-based therapy
resistance in HER2-positive breast cancer. Cancer Chemother
Pharmacol. 86:761–772. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Todorova VK, Byrum SD, Gies AJ, Haynie C,
Smith H, Reyna NS and Makhoul I: Circulating exosomal microRNAs as
predictive biomarkers of neoadjuvant chemotherapy response in
breast cancer. Curr Oncol. 29:613–630. 2022. View Article : Google Scholar : PubMed/NCBI
|
